Yamamoto® Research GLR® is formulated in fast dissolving sublingual tablets, where Setria-Glutathione will be rapidly absorbed by the sublingual tributary venous circulation of the superior vena cava, bypassing the intestinal activity of gamma-glutamyltransferase (absorption occurs at the buccal level), and avoiding enterocyte metabolic avidity and skipping the hepatic filter, preventing the first pass liver metabolism that largely deactivates the molecule, remembering that hepatocytes are particularly abundant.
GLR® is a dietary supplement based on Reduced Glutathione (Setria®), with vitamin C and selenium. In particular, both vitamin C and selenium contribute to the protection of cells from oxidative stress*, while vitamin C also contributes to the regeneration of the reduced form of vitamin E.
Glutathione is the body's first line of defence against oxidative stress and the many xenobiotics to which our organism is continually exposed (toxins, drugs, heavy metals, pesticides and others) that attack our cells and our enzymes. This accumulation of oxidative damage favours aging of the organism, as well as a greater predisposition to diseases, and the degradation of physiological functions, which become less efficient and more exposed to "external attacks". In fact there is a direct correlation between aging and reduction of intracellular glutathione concentration, as well as a strong correlation between the growth of these concentrations and the increase in the survival rate. With the support of a vast amount of scientific research, it is shown that optimal glutathione rates are essential to support the functionality of the immune system, to protect and detoxify the liver and kidneys, remove the risk of chronic diseases and promote longevity. It is called a "master antioxidant", as it is able to "recycle" other antioxidants such as vitamin C and E, alpha-lipoic acid, and coenzyme Q10, and when the levels of glutathione increase, consequently also the others antioxidants will undergo a favourable increase. Its oral intake has always been a controversial topic and left aside, as the human intestine contains important amounts of an enzyme, gamma-glutamyltranspeptidase, which degrades much of the ingested glutathione, so ingesting even high amounts of glutathione or other precursors did not lead to significant results that could compare or start on the injectable pathway.
GLR® is a new generation reduced Glutathione supplement, which combines two particular strategies that have improved the absorption and bioavailability of this precious antioxidant, effectively re-launching its oral version. GLR® is formulated in sublingual tablets containing reduced Setria-Glutathione, a particular formula patented by the Japanese multinational company Kyowa Hakko. An important study published in the European Journal of Nutrition revealed that the daily supplementation of Setria® glutathione increases glutathione reserves by 30-35% in 6 months.
The randomised, double-blind, placebo-controlled trial was conducted at the Penn State University School of Medicine by Dr John P. Richie Jr., Ph.D., Professor of Public Health and Pharmacology. Dr Richie has studied glutathione for over 25 years, paying particular attention to the ability of glutathione to combat oxidative stress..
"Within the scientific community it is known that glutathione is one of the main protective molecules in the body. It has long been discussed whether glutathione levels could be supplemented or not by taking oral glutathione, and clinical data was lacking," reported Dr Richie. The researcher's phrase is significant: "We now have the evidence to illustrate the potential benefits of glutathione supplementation." The study measured the effect of glutathione supplementation with Setria® on glutathione levels in 54 healthy adults between the ages of 28 and 72 years. A group of subjects were given 250 mg/day, a second group 1,000 mg/day, and a third group 470 mg/day of placebo. Glutathione levels were measured for six months in various parts of the blood, including erythrocytes (red blood cells) and lymphocytes (white blood cells), and in mucosal cells within the cheeks. The study showed that, with both doses, the levels of glutathione in the blood increased after one, three and six months compared to the baseline levels. After six months, mean glutathione levels increased 30-35% in erythrocytes, plasma and lymphocytes, and 260% in oral mucosa in the high dosage group. Another factor to consider, is that the study showed that daily supplementation of 1,000 mg/day increased the functionality of NK lymphocytes by more than a factor of two in three months. NK lymphocytes are key agents for the normal functioning of the immune system because they quickly identify and kill abnormal cells. This doubling of the cytotoxicity of NK cells means that NK lymphocytes are twice as effective in eliminating abnormal cells, such as those suffering from viral or tumour infections. A secondary analysis of the data also indicated that the daily supplementation of 250-1,000 mg of the patented Setria® formula can result in a strong decrease in oxidative stress in 6 months.
GLR® is formulated in fast dissolving sublingual tablets, where Setria-Glutathione will be rapidly absorbed by the sublingual tributary venous circulation of the superior vena cava, bypassing the intestinal activity of gamma-glutamyltransferase (absorption occurs at the buccal level), and avoiding enterocyte metabolic avidity and skipping the hepatic filter, preventing the first pass liver metabolism that largely deactivates the molecule, remembering that hepatocytes are particularly abundant. There are human studies that have shown that glutathione absorption is greatly increased when it is held in the mouth between the palate and the tongue, making it possible to take glutathione orally (1-3 times a day), which can bring serum and cellular concentrations to normal levels in a few hours, without necessarily having to go through the injection route to ensure effective bioavailability. Taking advantage of the most recent research activities in this regard, with GLR®, perlingual absorption in this way becomes an alternative route of rapid administration, and above all finally more effective than the very poorly absorbed preparations created in the past, in order to reinforce or restore optimal levels of the precious central element of the body's antioxidant defence system - and all this at an affordable cost.
30 tablets Mean analysis Per daily dose 1 chewable tablet Per daily dose (1 chewable tablet) L-Glutathione Reduced (Setria®)
80 mg (100% AR / RI **)
55 mcg (100% AR / RI **)
** AR / RI: reference assumptions
Ingredients: sweeteners: mannitol, sucralose; L-Glutathione Reduced (Setria®), L-ascorbic acid (vitamin C), anti-caking agents: silicon dioxide, magnesium salts of fatty acids; L-selenomethionine, mint essential oil.
SETRIA® is a registered trademark of KYOWA HAKKO BIO CO., LTD.
Directions: take 1-2 capsules a day, preferably after meal.
WARNINGS: do not exceed the recommended daily dose. The supplements are not intended as substitutes for a varied diet. A varied and balanced diet and a healthy lifestyle are important. Keep out of reach of children under three years. Store in a cool, dry place at room temperature. Avoid exposure to heat and sunlight. Do not disperse in the environment after use.